BioMarin Pharmaceutical Inc. (BMRN) DCF Valuation
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
BioMarin Pharmaceutical Inc. (BMRN) Bundle
Designed for accuracy, our [BMRN] DCF Calculator enables you to evaluate BioMarin Pharmaceutical Inc. valuation using up-to-date financial data and complete adaptability to modify all essential parameters for improved forecasts.
Discounted Cash Flow (DCF) - (USD MM)
Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue | 1,704.0 | 1,860.5 | 1,846.3 | 2,096.0 | 2,419.2 | 2,645.2 | 2,892.3 | 3,162.4 | 3,457.8 | 3,780.8 |
Revenue Growth, % | 0 | 9.18 | -0.76218 | 13.53 | 15.42 | 9.34 | 9.34 | 9.34 | 9.34 | 9.34 |
EBITDA | 33.9 | -5.9 | 48.0 | 267.5 | 310.3 | 158.0 | 172.8 | 188.9 | 206.6 | 225.8 |
EBITDA, % | 1.99 | -0.31444 | 2.6 | 12.76 | 12.83 | 5.97 | 5.97 | 5.97 | 5.97 | 5.97 |
Depreciation | 105.3 | 105.9 | 108.0 | 102.0 | 104.4 | 142.3 | 155.6 | 170.2 | 186.0 | 203.4 |
Depreciation, % | 6.18 | 5.69 | 5.85 | 4.86 | 4.31 | 5.38 | 5.38 | 5.38 | 5.38 | 5.38 |
EBIT | -71.4 | -111.7 | -60.0 | 165.5 | 205.9 | 15.7 | 17.2 | 18.8 | 20.5 | 22.4 |
EBIT, % | -4.19 | -6.01 | -3.25 | 7.9 | 8.51 | 0.59319 | 0.59319 | 0.59319 | 0.59319 | 0.59319 |
Total Cash | 753.8 | 1,065.4 | 1,013.9 | 1,291.5 | 1,073.8 | 1,388.3 | 1,518.0 | 1,659.8 | 1,814.8 | 1,984.3 |
Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Account Receivables | 377.4 | 448.4 | 373.4 | 461.3 | 633.7 | 606.7 | 663.3 | 725.3 | 793.1 | 867.1 |
Account Receivables, % | 22.15 | 24.1 | 20.22 | 22.01 | 26.19 | 22.93 | 22.93 | 22.93 | 22.93 | 22.93 |
Inventories | 680.3 | 698.5 | 776.7 | 894.1 | 1,107.2 | 1,100.2 | 1,202.9 | 1,315.3 | 1,438.2 | 1,572.5 |
Inventories, % | 39.92 | 37.55 | 42.07 | 42.66 | 45.77 | 41.59 | 41.59 | 41.59 | 41.59 | 41.59 |
Accounts Payable | 241.0 | 191.4 | 193.0 | 231.2 | 315.5 | 311.9 | 341.0 | 372.9 | 407.7 | 445.8 |
Accounts Payable, % | 14.14 | 10.29 | 10.45 | 11.03 | 13.04 | 11.79 | 11.79 | 11.79 | 11.79 | 11.79 |
Capital Expenditure | -163.4 | -137.5 | -119.2 | -131.5 | -107.6 | -180.7 | -197.6 | -216.1 | -236.3 | -258.3 |
Capital Expenditure, % | -9.59 | -7.39 | -6.46 | -6.28 | -4.45 | -6.83 | -6.83 | -6.83 | -6.83 | -6.83 |
Tax Rate, % | 11.09 | 11.09 | 11.09 | 11.09 | 11.09 | 11.09 | 11.09 | 11.09 | 11.09 | 11.09 |
EBITAT | -17.9 | 2,254.6 | -51.0 | 156.7 | 183.1 | 9.2 | 10.1 | 11.0 | 12.1 | 13.2 |
Depreciation | ||||||||||
Changes in Account Receivables | ||||||||||
Changes in Inventories | ||||||||||
Changes in Accounts Payable | ||||||||||
Capital Expenditure | ||||||||||
UFCF | -892.8 | 2,084.2 | -63.8 | -40.0 | -121.4 | 1.2 | -162.2 | -177.4 | -193.9 | -212.1 |
WACC, % | 5.54 | 5.45 | 5.75 | 5.78 | 5.76 | 5.65 | 5.65 | 5.65 | 5.65 | 5.65 |
PV UFCF | ||||||||||
SUM PV UFCF | -611.3 | |||||||||
Long Term Growth Rate, % | 4.00 | |||||||||
Free cash flow (T + 1) | -221 | |||||||||
Terminal Value | -13,339 | |||||||||
Present Terminal Value | -10,132 | |||||||||
Enterprise Value | -10,743 | |||||||||
Net Debt | 341 | |||||||||
Equity Value | -11,084 | |||||||||
Diluted Shares Outstanding, MM | 192 | |||||||||
Equity Value Per Share | -57.85 |
What You Will Get
- Real BMRN Financial Data: Pre-filled with BioMarin's historical and projected data for precise analysis.
- Fully Editable Template: Modify key inputs like revenue growth, WACC, and EBITDA % with ease.
- Automatic Calculations: See BioMarin’s intrinsic value update instantly based on your changes.
- Professional Valuation Tool: Designed for investors, analysts, and consultants seeking accurate DCF results.
- User-Friendly Design: Simple structure and clear instructions for all experience levels.
Key Features
- Real-Life BMRN Data: Pre-filled with BioMarin's historical financials and future growth estimates.
- Fully Customizable Inputs: Modify revenue growth rates, profit margins, discount rates, tax assumptions, and capital investments.
- Dynamic Valuation Model: Automatic recalculations of Net Present Value (NPV) and intrinsic value based on user-defined inputs.
- Scenario Testing: Develop various forecast scenarios to evaluate different valuation results.
- User-Friendly Design: Intuitive layout, crafted for both industry professionals and newcomers.
How It Works
- Download: Obtain the pre-built Excel file containing BioMarin Pharmaceutical Inc. (BMRN) financial data.
- Customize: Modify projections, such as revenue growth, EBITDA %, and WACC.
- Update Automatically: The intrinsic value and NPV calculations refresh in real-time.
- Test Scenarios: Generate various forecasts and instantly compare results.
- Make Decisions: Utilize the valuation findings to inform your investment strategy.
Why Choose This Calculator for BioMarin Pharmaceutical Inc. (BMRN)?
- Accurate Data: Real BioMarin financials guarantee trustworthy valuation outcomes.
- Customizable: Modify essential parameters such as growth rates, WACC, and tax rates to align with your forecasts.
- Time-Saving: Pre-built calculations save you the hassle of starting from the ground up.
- Professional-Grade Tool: Tailored for investors, analysts, and consultants in the pharmaceutical sector.
- User-Friendly: Easy-to-navigate design and comprehensive instructions ensure accessibility for all users.
Who Should Use This Product?
- Pharmaceutical Students: Explore drug development processes and apply them using real-world case studies.
- Researchers: Integrate advanced biopharmaceutical models into academic projects or publications.
- Investors: Evaluate your investment strategies and analyze valuation metrics for BioMarin Pharmaceutical Inc. (BMRN).
- Market Analysts: Enhance your analysis with a ready-to-use, customizable financial model tailored for the biotech sector.
- Healthcare Entrepreneurs: Understand the valuation methods applied to leading biotech firms like BioMarin Pharmaceutical Inc. (BMRN).
What the Template Contains
- Pre-Filled DCF Model: BioMarin Pharmaceutical Inc.’s (BMRN) financial data preloaded for immediate use.
- WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
- Financial Ratios: Evaluate BioMarin’s profitability, leverage, and efficiency.
- Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
- Financial Statements: Annual and quarterly reports to support detailed analysis.
- Interactive Dashboard: Easily visualize key valuation metrics and results.